Cover Image

A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma

Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin wer...

Full description

Saved in:
Bibliographic Details
Main Authors: Lopez, Juanita Suzanne (Author) , Haefliger, Simon (Author) , Plummer, Ruth (Author) , Clement, Paul M. (Author) , Jeffry Evans, Thomas R. (Author) , Läubli, Heinz (Author) , Roth, Patrick (Author) , Kristeleit, Rebecca (Author) , Brazil, Lucy (Author) , Tabatabai, Ghazaleh (Author) , Wick, Antje (Author) , Wunderlich, Benjamin (Author) , Beebe, Kirk (Author) , Eisner, Joel Robert (Author) , Lane, Heidi (Author) , Engelhardt, Marc (Author) , Kaindl, Thomas (Author) , Hau, Peter (Author) , Hundsberger, Thomas (Author) , Steinbach, Joachim (Author)
Format: Article (Journal)
Language:English
Published: 17 June 2025
In: Cell reports. Medicine
Year: 2025, Volume: 6, Issue: 6, Pages: 1-12
ISSN:2666-3791
DOI:10.1016/j.xcrm.2025.102165
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.xcrm.2025.102165
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2666379125002381
Get full text
Author Notes:Juanita Suzanne Lopez, Simon Haefliger, Ruth Plummer, Paul M. Clement, Thomas R. Jeffry Evans, Heinz Läubli, Patrick Roth, Rebecca Kristeleit, Lucy Brazil, Ghazaleh Tabatabai, Antje Wick, Benjamin Wunderlich, Kirk Beebe, Joel Robert Eisner, Heidi Lane, Marc Engelhardt, Thomas Kaindl, Peter Hau, Thomas Hundsberger, and Joachim Steinbach
Description
Summary:Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin were well tolerated with preliminary activity in recurrent glioblastoma. The current phase 1/2a study evaluates the safety and tolerability of once-daily oral lisavanbulin in patients with solid tumors or recurrent glioblastoma or high-grade glioma. Lisavanbulin is associated with profound, durable responses in a subset of patients with recurrent refractory grade 4 astrocytoma or glioblastoma. We present here the clinical and translational results from this trial, including a description of a response-predictive molecular signature that warrants further exploration in these tumor types of significant unmet need. The study is registered at ClinicalTrials.gov (NCT02490800).
Item Description:Online verfügbar: 17. Juni 2025, Artikelversion: 17. Juni 2025
Gesehen am 19.01.2026
Physical Description:Online Resource
ISSN:2666-3791
DOI:10.1016/j.xcrm.2025.102165

Similar Items